Lilly JVBA (IMCL CP12-1027): A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy
||Benjamin Levy, M.D., MD
| Time frame of study:
|Location of Study:
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center
Continuum Cancer Research Program
The standard therapy approved for Stage IV or advanced Non-Small Cell Lung Cancer is chemotherapy, either docetaxel or pemetrexed alone. This study is being done to determine the safety and effectiveness of ramucirumab (an investigational drug) when given with another chemotherapy drug (docetaxel) for subjects with this type of cancer. Subjects will either received docetaxel with ramucirumab or docetaxel with placebo (pill with no medicine).
- Subjects who have had disease during or after one and only one prior first-line platinum-based chemotherapy regimen (e.g., cisplatin).
- At least 18 years of age
- The subject has histologically or cytologically confirmed Stage IV Non-Small Cell Lung Cancer
- Subject is not pregnant or breast feeding.
Please call for more information